Mobile website
Archive > Volume 24 Issue 4 > 2017,24(4):411-416. DOI:10.3872/j.issn.1007-385X.2017.04.013 Prev Next
Clinical Research
Application of TMT quantitative proteomics in identification of differentially expressed serum proteins of breast cancer patients with axillary lymph node metastasis
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To indentify the differentially expressed proteins in serum among patients of breast cancer with and without axillary lymph node metastasis, and to screen the diagnostic biomarkers and therapeutic targets that related to breast cancer metastasis.Methods: Quantitative proteomics TMT（tandem mass tag）technology was used to detect and quantitatively analyze serum proteins of breast cancer patients with and without axillary lymph node metastasis (14 cases in each group), and to further screen significant differentially expressed proteins. Uniprot database and proteome discoverer software were applied to analyze the bioinformatics. Results:One hundred and nineteen differentially expressed proteins were identified, and 6 proteins were significantly up-regulated,113 proteins were significantly down-regulated. Gene ontology (GO) annotation and functional cluster analyses showed that these differentially expressed proteins are locate at extracellular domain, and correlate with biosynthesis, cell proliferation and angiogenesis of tumor. Western boltting and qRT-PCR verified that the expressions of K1C19 (down-regulated by 0.11 times) and PSME2 (up-regulated by 2.02 times). Conclusion: TMT quantitative proteomics is a compelling way to discover differentially expressed proteins of breast cancer patients with and without axillary lymph node metastasis, and K1C19 and PSME2 are the potential serum biomarkers that deserve further exploration.
Keywords:
Project Supported:
Projecte supported by the National Natural Science Foundation of China(No.8150111616)
Clc Number:
